RxDoctor Payments DataLook up a doctor →

Adeel Khan, MD

Pulmonary Disease · Washington, MONPI 1790993863

Payments from drug & device makers

$316,111in general payments, 2019–2025

Across 811 payments — averaging $389.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$295K
  • Boehringer Ingelheim$6K
  • Mylan Specialty L.p.$5K
  • Intuitive Surgical$4K
  • AstraZeneca$2K
  • Viiv Healthcare Company$600
  • plus $4K from 37 others

What the payments were for

  • Consulting fees$1750%
  • Speaking & faculty fees$288,63191%
  • Travel & lodging$13,9424%
  • Food & beverage$13,1294%
  • Education$2170%
  • Gifts$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$316,111 in reported general payments places this provider in the 90th percentile of 295 pulmonary disease providers in Missouri.

See all pulmonary disease providers in Missouri

Medicare billing

Part B allowed, 2024
$123,196
Medicare patients
582
Services billed
1,665

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter771$654,076
OfevNintedanib Esylate22$305,499
ZemairaAlpha-1-Proteinase Inhibitor13$143,109
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr209$128,534
Prolastin CAlpha-1-Proteinase Inhibitor13$125,697
Breztri AerosphereBudesonide/Glycopyr/Formoterol128$116,337
Breo ElliptaFluticasone/Vilanterol179$84,736
Stiolto RespimatTiotropium Br/Olodaterol Hcl95$51,498
Spiriva HandihalerTiotropium Bromide59$47,979
Spiriva RespimatTiotropium Bromide63$45,652
SymbicortBudesonide/Formoterol Fumarate129$37,546
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate74$21,456
Fluticasone-SalmeterolFluticasone Propion/Salmeterol151$18,943
ArexvyRsvpref3 Antigen/As01e/Pf73$18,579
Incruse ElliptaUmeclidinium Bromide45$17,967

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arexvy, Incruse Ellipta$294,674$907,2041,288 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Combivent Respimat$5,725$409,719192 claims
AstraZenecaBreztri Aerosphere, Symbicort, Bevespi Aerosphere$2,250$164,816283 claims
Grifols USA, LLCProlastin C$194$125,69713 claims
Johnson & JohnsonXarelto$22$10,06614 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 295 pulmonary disease providers in Missouri.

Other pulmonary disease in Washington

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →